ライフサイエンスコーパス: risk ratio

1 risk groups to maintain a favourable benefit-risk ratio.

2 hose patients who will have the best benefit/risk ratio.

3 rmacotherapy, to maximize the benefit versus risk ratio.

4 xcess cancer risk and lower MPI's benefit-to-risk ratio.

5 erapy) continues to have a favorable benefit-risk ratio.

6 odels were used to summarize odds ratios and risk ratios.

7 We used a random-effects model to pool risk ratios.

8 robust standard errors was used to estimate risk ratios.

9 %) of 680 patients in the risedronate group (risk ratio 0.44, 95% CI 0.29-0.68; p<0.0001).

10 s rate decreased from 0.24 to 0.10 (adjusted risk ratio 0.44, 95% confidence interval [CI] 0.26-0.75)

11 n of sepsis and death) in the treatment arm (risk ratio 0.60, 95% confidence interval 0.48-0.74), wit

12 ion in cardiac events compared with placebo (risk ratio 0.63 [95% CI 0.42-0.97]; p=0.0344).

13 th C (24.6%, 25.6%, and 36.4%, respectively; risk ratio 0.68 [95% confidence interval: 0.53-0.87] for

14 ion arm died in their first 28 days of life (risk ratio 0.76, 95% CI 0.64 to 0.90, p = 0.0018; risk d

15 CA-ineligible individuals (adjusted incident risk ratio 0.78, 95% CI 0.56-0.95, p=0.020) and were les

16 pared with 55 per 1000 in the control group (risk ratio 0.80, 95% CI 0.68-0.93; p=0.005).

17 event decreased from 0.30 to 0.23 (adjusted risk ratio 0.82, 95% CI 0.58-1.17).

18 with 66 (10%) in the placebo group (adjusted risk ratio 0.93 (95% CI 0.68-1.27); 73 (11%) infants in

19 after adjustment for potential confounders (risk ratio 0.94 per TTV log level; 95% confidence interv

20 ompared with 192 (54%) in the placebo group (risk ratio 0.94, 95% CI 0.81-1.08; p=0.366).

21 hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% confidence interval 0.2-0.4) or in

22 l 0.2-0.4) or infant HBV DNA seropositivity (risk ratio = 0.3, 95% confidence interval 0.2-0.5) at 6-

23 er PC mortality but only in the control arm (risk ratio = 0.45-0.73; P < 0.05).

24 ortality in both control and screening arms (risk ratio = 0.48-0.69; P < 0.05).

25 with decreased risk of all-cause mortality (risk ratio = 0.74, 95% confidence intervals: 0.55, 0.99)

26 standard-deviation increase in B12, adjusted risk ratio = 0.89, 95% CI: 0.82, 0.97).

27 ngle-organ failure (4.7% vs 20.3%; P = .007; risk ratio, 0.15; 95% CI, 0.03-0.60) and new-onset multi

28 % IRS protection reduced preterm birth risk (risk ratio, 0.35; 95% confidence interval, .15-.84), wit

29 ple-organ failure (15.6% vs 39.1%; P = .008; risk ratio, 0.40; 95% CI, 0.20-0.77) were also lower aft

30 ecreased secondary fungal infections by 50% (risk ratio, 0.49; 95% CI, 0.35-0.68; p = 0.0001).

31 a trend toward a reduction in constipation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p = 0.05; low-qual

32 detection included exclusive breastfeeding (risk ratio, 0.57; 95% confidence interval, .47-.67), tre

33 lower ventilator-associated pneumonia rates (risk ratio, 0.58; 95% CI, 0.51-0.67; I2 = 0%), but there

34 s associated with a 41% mortality reduction (risk ratio, 0.59; 95% CI, 0.48-0.73) and a 30% reduction

35 otal ALI events by 41% (94 versus 56 events; risk ratio, 0.59; 95% confidence interval, 0.38-0.93; P=

36 3), with continued gains through 1.75 years (risk ratio, 0.615; 95% CI, 0.609-0.662).

37 icans strains was observed during treatment (risk ratio, 0.62; 95% CI, 0.19-1.97; p = 0.42).

38 ups (risk ratio, 0.84; 95% CI, 0.77-0.92 and risk ratio, 0.64; 95% CI, 0.52-0.78, respectively), but

39 mab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84).

40 up versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P=0.04).

41 within 1 year of diagnosis than white women (risk ratio, 0.745; 95% CI, 0.60 to 0.93).

42 to a better outcome than initial intubation (risk ratio, 0.74; 95% CI, 0.65-0.84).

43 intraocular bleeding compared with warfarin (risk ratio, 0.78; 95% CI, 0.61-0.99).

44 nificant decrease in the risk of VTE events (risk ratio, 0.78; 95% CI, 0.72-0.85; P < .001).

45 associated with 18% reduction in mortality (risk ratio, 0.82; 95% CI, 0.70-0.96; p = 0.01) and a 35%

46 ients compared with other dosing strategies (risk ratio, 0.83; 95% CI, .74-.94; P = .015).

47 y in the intermediate- and high-risk groups (risk ratio, 0.84; 95% CI, 0.77-0.92 and risk ratio, 0.64

48 cillin group vs. 30.7% in the placebo group; risk ratio, 0.86; 95% CI, 0.76 to 0.98; P=0.02).

49 e to the noncooled group (adjusted posterior risk ratio, 0.86; 95% credible interval, 0.58-1.29).

50 ntive antifungal did not decrease mortality (risk ratio, 0.88; 95% CI, 0.74-1.04; p = 0.14) but signi

51 all covariate models (fully adjusted model: risk ratio, 0.89; 95% CI, 0.83-0.95), but associations w

52 sk ratio, 0.91 [0.89-0.93] versus HFmrEF and risk ratio, 0.90 [0.88-0.92] versus HFrEF).

53 ative benefits of SC were clear at 6 months (risk ratio, 0.905; 95% CI, 0.898-0.913), with continued

54 with or without additional vessel injuries (risk ratio, 0.90; 95% CI, 0.21-3.83).

55 arginal deterioration of neurologic outcome (risk ratio, 0.90; 95% CI, 0.80-1.01; p = 0.06).

56 were found in terms of all-cause mortality (risk ratio, 0.90; 95% confidence interval, 0.71-1.15; P=

57 lar for HFmrEF and HFrEF and lower in HFpEF (risk ratio, 0.91 [0.89-0.93] versus HFmrEF and risk rati

58 and health behaviors (fully adjusted model: risk ratio, 0.91; 95% CI, 0.80-1.04).

59 f 171 (31.6%) cooled for 120 hours (adjusted risk ratio, 0.92 [95% CI, 0.68-1.25]; adjusted absolute

60 2 (31.5%) cooled to 32.0 degrees C (adjusted risk ratio, 0.92 [95% CI, 0.68-1.26]; adjusted absolute

61 tio, 0.97; 95% CI, 0.65-1.43), or mortality (risk ratio, 0.93; 95% CI, 0.84-1.03; I2 = 0%).

62 no reduction in tolerance of enteral feeds (risk ratio, 0.94 [95% CI, 0.62-1.42]; p = 0.77; low-qual

63 n rate with ezetimibe compared with placebo (risk ratio, 0.95; 95% confidence interval, 0.90-0.99; P=

64 mbolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to

65 .30; I2 = 0%), ventilator-associated events (risk ratio, 0.97; 95% CI, 0.65-1.43), or mortality (risk

66 r continuation of antidepressant medication (risk ratio: 0.674; 95% CI=0.482-0.943; number needed to

67 antidepressants alone or treatment as usual (risk ratio: 0.811; 95% CI=0.685-0.961; number needed to

68 time image integration (R(2)=0.21; P=0.0006; risk ratio=0.49 [0.33-0.74]), and the use of multipolar

69 plete LAVA elimination (R(2)=0.29; P<0.0001; risk ratio=0.52 [0.38-0.70]), the use of real-time image

70 of multipolar catheters (R(2)=0.08; P=0.05; risk ratio=0.75 [0.56-1.00]).

71 d with 102 (29%) women in the control group (risk ratio 1.0, 95% CI 0.79-1.25; p=0.96).

72 d no overall intervention effect (n = 6399) (risk ratio 1.05; 95% CI, 0.74-1.50; P = .78).

73 pared to 13 (0.20%) in the intervention arm (risk ratio 1.24, 95% CI 0.53 to 2.90, p = 0.6176; 1 deat

74 cant overall intervention effect (n = 1293) (risk ratio 1.53; 95% CI, 1.10-2.14; P = .01).

75 d with 29% of patients in the POWeR+F group (risk ratio 1.56, 0.96-2.51; p=0.070) and 32% of patients

76 ared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI: 1.0, 1.2, P = .005).

77 sk of low birth weight in newborns (adjusted risk ratio = 1.15, 95% confidence interval (CI): 1.01, 1

78 ith a higher risk of preterm birth (adjusted risk ratio = 1.21, 95% CI: 0.99, 1.49).

79 not of hospitalization without an infection (risk ratio = 1.4, 95% confidence interval: 0.9, 2.1, P =

80 did not increase the overall risk of death (risk ratio, 1.02; 95% CI, 0.93-1.13).

81 sed with the number of microemboli (adjusted risk ratio, 1.03/microembolus/hr; 95% CI, 1.01-1.05) and

82 noninvasive mechanical ventilation failure (risk ratio, 1.07; 95% CI, 1.00-1.14).

83 therapy did not decrease treatment failures (risk ratio, 1.13; 95% CI, 0.92 to 1.38; P = 0.23), and n

84 0.51), and 30-day postimplant complications (risk ratio, 1.18; 95% confidence interval, 0.87-1.60; P=

85 d for race/ethnicity, age, and sex (adjusted risk ratio, 1.23; 95% CI, 1.08-1.15; and 1.62; 95% CI, 1

86 1-1.15; P=0.41), composite efficacy outcome (risk ratio, 1.24; 95% confidence interval, 0.65-3.37; P=

87 dies indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to deve

88 r numbers of all genital HPV types (relative risk ratio, 1.26; 95% confidence interval, 1.03-1.54) an

89 espectively), but not in the low-risk group (risk ratio, 1.278; 95% CI, 0.888-1.839).

90 indications for cesarean delivery (adjusted risk ratio, 1.30; 95% CI, 1.09-1.54; P = .004).

91 and a 35% improvement in neurologic outcome (risk ratio, 1.35; 95% CI, 1.18-1.54; p < 0.00001).

92 95% CI, 1.76-3.68) and microbleeds (adjusted risk ratio, 1.43; 95% CI, 1.18-1.72) and a greater 5-yea

93 s among those with asthma in crude analyses (risk ratio, 1.48; 95% CI, 1.24-1.36; and 1.97; 95% CI, 1

94 thma, by 50% and 20%, respectively (weighted risk ratio, 1.5 and 1.2; 95% confidence interval, 1.2-1.

95 Previous hospitalization (risk ratio, 1.57 [95% CI, 1.07-2.31]) or antibiotic use

96 1.57 [95% CI, 1.07-2.31]) or antibiotic use (risk ratio, 1.65 [95% CI, 1.15-2.37]) and exposure to be

97 treatment with a 66% increase in mortality (risk ratio, 1.66; 95% CI, 1.06-2.59; p = 0.03) and a mar

98 e to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.24-2.56]) and carbapenems (r

99 ns were associated with all-cause mortality (risk ratio, 1.78; 95% CI, 1.01-3.15; I = 43%) and unfavo

100 stly increased the risk of infant pertussis (risk ratio, 1.8 [95% CI, .5-6.9]).

101 isk, 15.6% [95% CI, 6.9% to 24.3%]; adjusted risk ratio, 1.87 [CI, 1.17 to 2.98]).

102 th benign lesions, 51 (36%) with correlates (risk ratio, 1.92; 95% CI: 1.001, 3.695; two-tailed P = .

103 f a restorative intervention almost doubled (risk ratio, 1.98; 95% CI, 1.68-2.33) in high caries risk

104 t of care associated with 7 of 9 procedures (risk ratios, 1.23-1.35; P < .05).

105 % vs. 7.2%; absolute risk difference: +2.4%; risk ratio: 1.32; 95% confidence interval: 1.10 to 1.59;

106 (91 of 351) in the control group (p = 0.002; risk ratio: 1.43; 95% confidence interval: 1.14 to 1.78)

107 95% CI=-0.57 to -0.06), and responder rate (risk ratio: 1.52, 95% CI=1.29 to 1.78; number-needed-to-

108 < 0.0001) and high triglycerides (prevalence risk ratio 14.3/5.8, 2.5, p = 0.033).

109 ve transcranial Dopplers over multiple days (risk ratio, 16.0; 95% CI, 2.00-127.93).

110 r risk of hospitalization with an infection (risk ratio = 2.8, 95% confidence interval: 1.3, 5.9, P <

111 increased in GBS-associated NE vs NE alone (risk ratio, 2.07 [95% CI, 1.47-2.91]).

112 , 1.78 [95% CI, 1.24-2.56]) and carbapenems (risk ratio, 2.13 [95% CI, 1.49-3.06]) during the ICU sta

113 d risk of unfavorable Glasgow Outcome Scale (risk ratio, 2.46; 95% CI, 1.06-5.69; I = 74%).

114 43%) and unfavorable Glasgow Outcome Scale (risk ratio, 2.49; 95% CI, 1.72-3.58; I = 81%) at greater

115 k of incident subcortical infarcts (adjusted risk ratio, 2.54; 95% CI, 1.76-3.68) and microbleeds (ad

116 rsus 0.18% among unexposed infants (adjusted risk ratio, 2.66; 95% CI, 1.00 to 7.06).

117 ternal carotid artery injury grade (adjusted risk ratio, 2.91; 95% CI, 1.42-5.97).

118 ad a significant positive effect on NP role (risk ratio=2.33; 95% CI: 1.06-5.13); with a one unit inc

119 t 28 days (nine [31%] vs three [10%] deaths; risk ratio 3.2, 95% CI 1.0 to 10.7, p=0.054).

120 n in the active surveillance group (adjusted risk ratio 3.67, 95% CI 2.53-5.33; p<0.0001).

121 with a 3-fold increase in 30-day mortality (risk ratio, 3.16 [95% confidence interval, 1.96-5.09]).

122 % vs. 0.7%; absolute risk difference: +1.7%; risk ratio: 3.15; 95% confidence interval: 1.87 to 5.30;

123 nonsignificant risk of LTBI among diabetics (risk ratio, 4.40; 95% confidence interval [CI], 0.50-38.

124 0.0001), higher body mass index (prevalence risk ratio 40.5/4.8, 8.4, p < 0/0001),higher HOMA-IR (3.

125 mase-producing Enterobacteriaceae infection (risk ratio, 49.62 [95% CI, 20.42-120.58]).

126 al problems included consumption of cassava (risk ratio 5.68, 95% CI 3.22-10.03), perinatal complicat

127 ore stroke, compared with 46 of 248 without (risk ratio, 5.05; 95% CI, 1.41-18.13).

128 .02), higher waist circumference (prevalence risk ratio 83.3/20.3, 4.1, p < 0.0001), higher body mass

129 For prostatectomy, the risk ratios (95% CIs) for undergoing a robotic-assisted

130 Adjusted prevalence risk ratios (adjPRR) of detectable HIV shedding (VL > 40

131 significantly with age (adjusted prevelance risk ratio [adjPRR] = 0.53; 95% confidence interval [CI]

132 erinatal death (0.08% versus 0.26%; adjusted risk ratio [adjRR] 0.33; 95% CI 0.13-0.80, P = 0.015) an

133 Risk ratios and 95% confidence intervals were estimated

134 Risk ratios and 95% confidence intervals were extracted

135 ation are evaluated by estimating detectable risk ratios and necessary sample sizes for different stu

136 We also quantified differences with relative risk ratios and relative and slope indices of inequality

137 Risk ratios and the relative excessive risk due to inter

138 Results are expressed as risk ratios and their 95% CIs.

139 Risk differences (RD), risk ratios, and 95% confidence intervals (CIs) were est

140 ures was performed and odds ratios, relative risk ratios, and 95% confidence intervals were estimated

141 BSGI, annual screening benefit-to-radiation risk ratios are estimated to be 5 for women 40-49 years

142 d with an increased risk of asthma (adjusted risk ratio (aRR) = 1.22, 95% confidence interval (CI): 1

143 le models were used to estimate the adjusted risk ratio (aRR) for receiving an HCV antibody test, and

144 We estimated model-adjusted risk ratios (aRR) of anti-HCV-positive (anti-HCV+) ident

145 red to 7.7% among uninfected women (adjusted risk ratio [aRR] 1.14 [95% confidence interval (CI): 0.9

146 risk of iGAS in all racial groups (adjusted risk ratio [aRR] ranged from 2.71 to 5.08).

147 ; 95% CI, -5.63 to -4.10; P < .001; adjusted risk ratio [ARR], 0.21; 95% CI, 0.15 to 0.29; P < .001).

148 use between black and white women (adjusted risk ratio [aRR], 0.51; 95% CI, 0.35 to 0.74) but not in

149 characteristics and year of birth (adjusted risk ratio [aRR], 1.28; 95% CI, 1.15-1.42).

150 vely associated with HIV infection (adjusted risk ratio [aRR], 2.4; 95% confidence interval [CI], 1.4

151 .9% among those >/=80 years of age (adjusted risk ratio [aRR]: 2.01; 95% confidence interval [CI]: 1.

152 Adjusted relative risk ratios (aRRR) for associations of parental clinical

153 before and 13% after ACA; adjusted relative risk ratio [ARRR], 0.44; 95% confidence interval [CI], .

154 ear regression was used to estimate adjusted risk ratios (aRRs) and 95% CIs, after adjusting for mate

155 n, clinical improvement at 1 week (corrected risk ratios [cRR], 3.5 [2.3-3.8]; P = 0.001) was predict

156 We calculated MPI's benefit-to-risk ratios, defined by the annualized predicted MACE-to

157 Risk ratio estimates were calculated based on the number

158 e in the likelihood of nutritional recovery (risk ratio for amoxicillin vs. placebo, 1.05; 95% confid

159 The adjusted risk ratio for cardiac malformations among infants expos

160 In 12 trials reporting mortality, the risk ratio for death associated with dynamic assessment

161 ted with the risk of HIV infection (adjusted risk ratio for each time named, 1.9; P<0.001).

162 lend further support to the positive benefit-risk ratio for ibrutinib in relapsed or refractory mantl

163 tamin A supplementation on mortality by sex; risk ratio for mortality at 6 months for boys was 1.08 (

164 peutic approach, which maximizes the benefit:risk ratio for muscle diseases in man.

165 Intraocular bleeding events and associated risk ratio for novel oral anticoagulants compared with w

166 The adjusted risk ratio for obesity among offspring delivered via ces

167 The benefit-to-risk ratio for osteoporosis treatment is strongly positi

168 The pooled risk ratio for overall mortality was 0.81 (95% CI, 0.70-

169 The pooled risk ratio for relapse/recurrence was 0.781 (95% confide

170 Cohort-specific crude and adjusted risk ratios for asthma at ages 5-9 years were calculated

171 We estimated risk ratios for behavioral problems in children after pr

172 Incidence risk ratios for liver-specific and overall mortality for

173 We calculated detectable risk ratios for preterm birth in vaccinated versus unvac

174 ups will be extremely challenging to detect (risk ratios for preterm birth of 0.9 to 1.0) and will re

175 Estimated risk ratios from meta-analysis indicated that CAG-treate

176 We extracted and pooled adjusted risk ratios from prospective studies and standard mean d

177 independent variable) on deviation of pooled risk ratios from study baseline (dependent variable).

178 Risk ratios generally increased with longer moving avera

179 ies than in trading (age-adjusted prevalence risk ratio in men 0.64, 95% CI 0.44-0.97; women 0.53, 0.

180 Main Outcomes and Measures: Incidence risk ratios (IRRs) for stroke per age cohort, defined as

181 Results The benefit-to-radiation risk ratio is estimated to be 13 for women who are 40-49

182 (0.17 [CI, 0.15 to 0.19]) group, yielding a risk ratio of 0.75 (CI, 0.64 to 0.89).

183 ention studies included, the pooled relative risk ratio of AD in those treated with synbiotics compar

184 The primary outcome was a composite risk ratio of death, acute myocardial infarction, or isc

185 The risk ratio of depression and anxiety 3 years after admis

186 m over time, which may affect the benefit-to-risk ratio of guideline-recommended antithrombotic thera

187 Western immigrants had a significantly lower risk ratio of hospital attendance for anaphylaxis compar

188 The benefit-to-risk ratio of long-term antibiotic use should be careful

189 utcomes were cumulative incidence (risk) and risk ratio of new-onset psychiatrist-diagnosed depressio

190 nts should carefully consider the benefit-to-risk ratio of olanzapine and its additional, prophylacti

191 s to be better informed about the benefit-to-risk ratio of procedures, and guide allotment of limited

192 , it does not match the benefit-to-radiation risk ratio of screening mammography.

193 icant impacts on E. coli concentration, with risk ratios of 1.38 (95% CI = 1.16, 1.65), 1.07 (95% CI:

194 ic IgE to cat >= 3.5 kU/l presented relative risk ratios of 11.4 (95% CI 6.7-19.2), 18.8 (8.2-42.8),

195 ocardial infarction patients, HRT had pooled risk ratios of 3.53 (95% confidence interval [CI], 2.54-

196 Purpose To estimate the benefit-to-radiation risk ratios of mammography alone, breast-specific gamma

197 diation VII report, the benefit-to-radiation risk ratios of mammography alone, BSGI alone, and mammog

198 Compared with threshold 500, the 24 month risk ratios of virological failure (viral load more than

199 death and of AIDS-defining illness or death, risk ratios of virological failure, and mean differences

200 in the Bruneck Study, multivariable adjusted risk ratios per one-SD higher log miR-122 were 1.60 (95%

201 The hazard ratio (HR) point estimates and risk ratio point estimates corresponding to odds ratios

202 onary disease, and pneumonia mortality, with risk ratios ranging from 1.10 to 1.24.

203 d with a substantial reduction in mortality [risk ratio (RR) 0.63, 95% confidence interval (CI) 0.49-

204 mulative incidence of AR was lower in eHF-C (risk ratio (RR) 0.77, 95% CI 0.59-0.99]) and the AR prev

205 to patients without AR (age and sex-adjusted risk ratio (RR) 3.04; 95% confidence interval (95%CI) 2.

206 Ds after 4 years among women (for back MSDs, risk ratio (RR) = 1.58, 95% confidence interval (CI): 1.

207 We used the risk ratio (RR) and corresponding 95% CIs as the primary

208 om-effects models were used to summarize the risk ratio (RR) and mean differences.

209 n was extracted; summary mean difference and risk ratio (RR) estimates were synthesized under a rando

210 We estimated the risk ratio (RR) for preterm birth with maternal GBS colo

211 The adjusted risk ratio (RR) for psychiatric and neurodevelopmental d

212 The unadjusted risk ratio (RR) of being retained at 12 months with HIV-

213 enszel test or inverse variance to calculate risk ratio (RR) or mean difference (MD) with 95% confide

214 erformed a network meta-analysis to estimate risk ratio (RR) with 95% confidence interval (CI).

215 The risk ratio (RR), the number-needed-to-treat/harm (NNT/NN

216 compliance aids (9.3% and 3.1% respectively, risk ratio (RR)=3.9, 95% confidence interval (CI) 2.4 to

217 Risk ratios (RR) were pooled for good versus poor collat

218 ct comparisons showed that use of metformin (risk ratio [RR] 0.49, 95% CI 0.25-0.97) was associated w

219 lure when using e-POCT compared to ALMANACH (risk ratio [RR] 0.57, 95% CI 0.38, 0.85, p = 0.005).

220 -agent prophylaxis (190/12,834, 1.48%; crude risk ratio [RR] 0.64, 95% CI 0.49, 0.85; adjusted RR 0.6

221 ll-cause mortality than short-term infusion (risk ratio [RR] 0.70, 95% CI 0.56-0.87).

222 d with a significant reduction in morbidity (risk ratio [RR] 0.76, 95% confidence interval [CI] 0.66-

223 ere lower among females compared with males (risk ratio [RR] 0.78, 95 % CI 0.77-0.79).

224 al risk of under-5 child mortality (adjusted risk ratio [RR] 0.84, 95% CI 0.74-0.96).

225 s greater in areas with higher PM2.5 levels (Risk ratio [RR] 1.041, 95% Confidence Interval [CI], 1.0

226 utcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1.06 [95% CI 0.88-1.28; p=0.554]).

227 ntion group versus 40% in the control group, risk ratio [RR] 1.08 [95% CI 0.94 to 1.24; p = 0.252]; d

228 th standard repair vs 34/435 [8%] with mesh, risk ratio [RR] 1.08, 95% CI 0.68 to 1.72; p=0.73; graft

229 e control group (72%) were retained in care (risk ratio [RR] 1.11; 95% CI 1.00-1.24).

230 care group (13.6 deaths per 1000 livebirths; risk ratio [RR] 1.12, 95% CI 0.88-1.44).

231 th an increased risk of all-cause mortality (risk ratio [RR] 1.14 [95% CI 1.05-1.24] for streptokinas

232 associated with increased plaque formation (risk ratio [RR] 1.24, 95% confidence interval [CI] 1.07-

233 n the standard of care arm, both at 1 month (risk ratio [RR] 1.33, 95% CI 1.17-1.51, p < 0.001) and a

234 ence in HIV-positive men of any tobacco use (risk ratio [RR] 1.41 [95% CI 1.26-1.57]) and tobacco smo

235 edictors of non-testing included being male (risk ratio [RR] 1.52, 95% CI 1.48-1.56), single marital

236 period of high influenza virus circulation (risk ratio [RR] = 0.56, 95% confidence interval [CI], .4

237 against clinical respiratory illness (CRI) (risk ratio [RR] = 0.59; 95% confidence interval [CI]:0.4

238 =10 years were less likely to have a result (risk ratio [RR] = 0.72; 95% CI, 0.64-0.81 and RR = 0.49;

239 .3%) vs 8407 of 43314 (19.4%), respectively (risk ratio [RR] = 0.84; 95% CI, 0.81-0.87; P < .001).

240 f-care arm (delivery versus standard of care risk ratio [RR] = 1.07, 95% CI 0.99-1.15, P = 0.10; coup

241 as associated with a high colonization risk (risk ratio [RR] = 1.63; 95% CI, 1.19, 2.24 and RR = 1.58

242 oved alanine aminotransferase normalization (risk ratio [RR] = 2.3, 95% confidence interval [CI] 1.7-

243 had a higher risk for dual-strain infection (risk ratio [RR] = 9.20, 95% CI = 2.05-41.32), as did peo

244 0.21; calculation impairment 22% versus 26%, risk ratio [RR] [95% CI] = 0.86 [0.67-1.11], p = 0.24).

245 ith a lower risk of type 2 diabetes overall (risk ratio [RR] per interquintile range 0.65, 95% CI 0.6

246 hemotherapy as compared with white patients (risk ratio [RR], .82; 95% CI, .72 to .93).

247 er CAG was reduced by 55% compared with AMT (risk ratio [RR], 0.45, 95% CI, 0.21-0.99).

248 and provided greater spectacle independence (risk ratio [RR], 0.51; 95% CI, 0.36-0.71) and moderate q

249 to 6.6% among individuals administered ECT (risk ratio [RR], 0.54; 95% CI, 0.28-0.81).

250 ths was associated with reduced egg allergy (risk ratio [RR], 0.56; 95% CI, 0.36-0.87; I2 = 36%; P =

251 failure in comparison with head-box oxygen (risk ratio [RR], 0.59; 95% CI, 0.48-0.72; number needed

252 with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; a

253 with a reduction in total cancer mortality (risk ratio [RR], 0.86 [CI, 0.82 to 0.91]; 13 studies) an

254 atistically significant mortality reduction (risk ratio [RR], 0.86; 95% CI, 0.73-1.02).

255 intubated (411/1135 [36%] vs 460/1135 [41%]; risk ratio [RR], 0.89 [95% CI, 0.81-0.99]; P = .03).

256 erence [RD], 0.01; 95% CI, -0.07 to 0.10 and risk ratio [RR], 0.96; 95% CI, 0.77 to 1.21).

257 did not differ between groups at 12 months (risk ratio [RR], 1.01 [95% CI, 0.87 to 1.18]) and 24 mon

258 nd any breastfeeding for less than 3 months (risk ratio [RR], 1.07 [95% CI, 1.03-1.11]; 26 studies [n

259 cantly higher with CHWs vs MUMs: 87% vs 82% (risk ratio [RR], 1.1 [95% CI, 1.0-1.1]; P < .0001).

260 with higher odds of having conduct problems (risk ratio [RR], 1.42; 95% CI, 1.25-1.62) and hyperactiv

261 847) were at increased risk for incident RA (risk ratio [RR], 1.72; 95% CI, 1.25-2.37) and/or IBD (CD

262 luding having no educational qualifications (risk ratio [RR], 1.86 [95% CI, 1.69-2.04]), having a hig

263 VR was associated with a higher risk of PPI (risk ratio [RR], 2.18; 95% confidence interval [CI], 1.2

264 esence, compared with patients without CMBs (risk ratio [RR], 2.36; 95% CI, 1.21-4.61; P = .01).

265 ents to be diagnosed with melanoma (adjusted risk ratio [RR], 2.4; 95% CI, 1.7-3.4; P < .001) and to

266 ing done everything that was possible (crude risk ratio [RR], 3.5; 95% CI, 2.3 to 5.1) and for having

267 h an increased risk of future heart failure (risk ratio [RR], 4.19; 95% confidence interval [CI], 2.0

268 following: Breslow thickness exceeding 2 mm (risk ratio [RR], 9.64; 95% CI, 1.30-71.52), invasion bey

269 tients with SMR (17 studies, 26359 patients; risk ratio [RR],1.79; 95% CI, 1.47-2.18; P < .001, I2 =

270 ients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.8

271 low-volume hospitals (low tercile: relative risk ratio (RRR) = 2.57, P = 0.002; high tercile: RRR =

272 patients who were aged 16-30 years (relative risk ratio [RRR] 1.21, 95% CI 1.19-1.23) or older than 9

273 with immunocompetent comorbidities (relative risk ratio [RRR], 0.93; 95% confidence interval [CI], .6

274 Risk ratios (RRs) and 95% confidence intervals (CIs) wer

275 and interactions were estimated as adjusted risk ratios (RRs) and 95% confidence intervals (CIs).

276 Crude risk ratios (RRs) and 95% confidence intervals for each

277 as used to calculate unadjusted and adjusted risk ratios (RRs) and associated 95% confidence interval

278 Log-binomial models were used to estimate risk ratios (RRs) and corresponding 95% CIs for severe i

279 ersus ranibizumab are presented as estimated risk ratios (RRs) and mean differences (MDs) with 95% co

280 s that reported the odds ratios (ORs) and/or risk ratios (RRs) for adverse events with and without un

281 standardized mean differences (Hedges g) and risk ratios (RRs) for adverse events, were assessed in a

282 Data were summarized using risk ratios (RRs) for number of deaths/recurrences and h

283 andard errors were used to estimate adjusted risk ratios (RRs) to model risk of delay in definitive s

284 Summary estimates risk ratios (RRs) were constructed.

285 Weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) we

286 time and associations with social position (risk ratios [RRs] and 95% confidence intervals) were ana

287 the minimum strength of association, on the risk ratio scale, that an unmeasured confounder would ne

288 mmography plus BSGI has benefit-to-radiation risk ratios similar to those of BSGI alone.

289 We applied risk ratios to estimate numbers of preterm births attrib

290 h spontaneous vaginal delivery, the adjusted risk ratio was 1.33 (95% CI: 1.02, 1.75) for elective ce

291 oduced significant heterogeneity, the pooled risk ratio was 1.35 (95% CI, 1.11-1.65).

292 ial regression, the corresponding unadjusted risk ratio was 1.40 (95% confidence interval (CI): 1.30,

293 l status, race/ethnicity, and education, the risk ratio was 1.68 (95% CI: 1.56, 1.81).

294 MBq) BSGI has estimated benefit-to-radiation risk ratios well in excess of 1 for screening of asympto

295 Risk ratios were calculated with generalized linear mode

296 The crude risk ratios were pooled (cpRR) using a random-effects mo

297 as standardized mean difference /Hedges g or risk ratio, were compared separately for combinations wi

298 Risk ratios with 95% CIs were calculated.

299 and without pCR and compared using relative risk ratios with 95% CIs.

300 Adjusted risk ratios with parent-reported wheezing phenotypes and